29 Jun June 29, 2019August 15, 2022curevovaccine Events No Comments Dr. Corey Casper presented CRV-101’s upcoming clincial studies in US and discussed its potential for reduced reactogenicity. Share this: Share on X (Opens in new window) X Share on Facebook (Opens in new window) Facebook Share on Bluesky (Opens in new window) Bluesky Like this:Like Loading… clinical studiesCRV-101Scientific researchSHINGLES
